Credit Suisse Group (CS) Fundamental Analysis & Valuation

NYSE:CS • US2254011081

Current stock price

0.8858 USD
+0.01 (+0.99%)
At close:
0.899 USD
+0.01 (+1.49%)
After Hours:

This CS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CS Profitability Analysis

1.1 Basic Checks

  • CS had negative earnings in the past year.
CS Yearly Net Income VS EBIT VS OCF VS FCFCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10B -10B 20B 30B

1.2 Ratios

  • With a Return On Assets value of 1.00%, CS perfoms like the industry average, outperforming 48.02% of the companies in the same industry.
  • CS has a Return On Equity of 10.01%. This is in the better half of the industry: CS outperforms 69.31% of its industry peers.
Industry RankSector Rank
ROA 1%
ROE 10.01%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CS Yearly ROA, ROE, ROICCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 5 -5 -10 -15

1.3 Margins

  • CS has a better Profit Margin (18.68%) than 64.85% of its industry peers.
  • The Operating Margin and Gross Margin are not available for CS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 18.68%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CS Yearly Profit, Operating, Gross MarginsCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. CS Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CS has been increased compared to 1 year ago.
  • Compared to 1 year ago, CS has a worse debt to assets ratio.
CS Yearly Shares OutstandingCS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B
CS Yearly Total Debt VS Total AssetsCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200B 400B 600B 800B

2.2 Solvency

  • A Debt/Equity ratio of 2.80 is on the high side and indicates that CS has dependencies on debt financing.
  • CS has a Debt to Equity ratio of 2.80. This is amonst the worse of the industry: CS underperforms 84.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
CS Yearly LT Debt VS Equity VS FCFCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50B 100B 150B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CS Yearly Current Assets VS Current LiabilitesCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50B 100B 150B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CS Growth Analysis

3.1 Past

  • The earnings per share for CS have decreased strongly by -702.95% in the last year.
  • Looking at the last year, CS shows a very strong growth in Revenue. The Revenue has grown by 48.34%.
  • CS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.52% yearly.
EPS 1Y (TTM)-702.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-576.1%
Revenue 1Y (TTM)48.34%
Revenue growth 3Y-12.77%
Revenue growth 5Y-6.52%
Sales Q2Q%318.56%

3.2 Future

  • The Earnings Per Share is expected to grow by 16.46% on average over the next years. This is quite good.
  • CS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.57% yearly.
EPS Next Y82.2%
EPS Next 2Y39.87%
EPS Next 3Y27.69%
EPS Next 5Y16.46%
Revenue Next Year-4.81%
Revenue Next 2Y-0.32%
Revenue Next 3Y0.61%
Revenue Next 5Y2.57%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CS Yearly Revenue VS EstimatesCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B 25B
CS Yearly EPS VS EstimatesCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. CS Valuation Analysis

4.1 Price/Earnings Ratio

  • CS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CS Price Earnings VS Forward Price EarningsCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CS Per share dataCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • CS's earnings are expected to grow with 27.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y27.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CS Dividend Analysis

5.1 Amount

  • CS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CS Fundamentals: All Metrics, Ratios and Statistics

Credit Suisse Group

NYSE:CS (6/9/2023, 8:04:01 PM)

After market: 0.899 +0.01 (+1.49%)

0.8858

+0.01 (+0.99%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)04-24
Earnings (Next)07-27
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.50B
Revenue(TTM)28.98B
Net Income(TTM)5.41B
Analysts46.09
Price Target1.51 (70.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-126.63%
Min EPS beat(2)-230.24%
Max EPS beat(2)-23.02%
EPS beat(4)0
Avg EPS beat(4)-3226.79%
Min EPS beat(4)-11871.5%
Max EPS beat(4)-23.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)174.77%
Min Revenue beat(2)-4.76%
Max Revenue beat(2)354.29%
Revenue beat(4)1
Avg Revenue beat(4)84.46%
Min Revenue beat(4)-9.84%
Max Revenue beat(4)354.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.18%
PT rev (3m)-56.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-45.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.06
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.24
BVpS15.38
TBVpS14.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1%
ROE 10.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 18.68%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)72.35%
Cap/Depr(5y)87.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-702.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-576.1%
EPS Next Y82.2%
EPS Next 2Y39.87%
EPS Next 3Y27.69%
EPS Next 5Y16.46%
Revenue 1Y (TTM)48.34%
Revenue growth 3Y-12.77%
Revenue growth 5Y-6.52%
Sales Q2Q%318.56%
Revenue Next Year-4.81%
Revenue Next 2Y-0.32%
Revenue Next 3Y0.61%
Revenue Next 5Y2.57%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.83%
EBIT Next 3Y24.95%
EBIT Next 5YN/A
FCF growth 1Y-65.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.59%
OCF growth 3YN/A
OCF growth 5YN/A

Credit Suisse Group / CS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Credit Suisse Group (CS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CS.


What is the valuation status of Credit Suisse Group (CS) stock?

ChartMill assigns a valuation rating of 3 / 10 to Credit Suisse Group (CS). This can be considered as Overvalued.


What is the profitability of CS stock?

Credit Suisse Group (CS) has a profitability rating of 2 / 10.


Can you provide the financial health for CS stock?

The financial health rating of Credit Suisse Group (CS) is 0 / 10.